ArticleBMC public health2025
Synergistic effects of outdoor nighttime light, air pollution, and PM
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension, dyslipidemia, and liver diseases often coexist as multimorbidity, yet its assocaition with environmental drivers like nighttime light (NL) and air pollution remain underexplored. This study investigates the independent and joint effects of NL, air pollutants, and PM2.5 components on multimorbidity risk.
methodsBased on data from the China Health and Retirement Longitudinal Study (2015–2020), we analyzed 11,216 adults aged 45 years and older who did not have multiple chronic conditions at baseline. We adjusted the covariates, including age, gender, education level, marital status, smoking status, drinking status, and sleep state. We employed Cox models that incorporated various combinations of these covariates to estimate the hazard ratios (HR). The exposure variables included NL, sulfur dioxide (SO₂), carbon monoxide (CO), ozone (O₃), nitrogen dioxide (NO₂), and particulate matter (PM₁, PM2.5, PM₁₀), along with components of PM2.5 (black carbon [BC], organic matter [OM], nitrate [NO₃⁻], sulfate [SO42-], and ammonium [NH4+]). Dose-response relationships and synergistic effects were quantified using restricted cubic spline functions and interaction analyses.
resultsDuring a median follow-up period of five years, 1,504 participants (13.4%) developed multiple conditions. A significant dose-response relationship (P < 0.05) was observed between the risks of multiple diseases and NL, as well as several air pollutants, including PM1, PM2.5, PM10, NO₂, SO₂, CO and components of PM2.5 (BC, OM, NO₃⁻, SO₄²⁻, and NH₄⁺), with the exception of O₃. The relative excess risk in interaction (RERI) for NL and PM₁ was 0.24 (95% CI: 0.01–0.46), for PM2.5 it was 0.26 (95% CI: 0.03–0.48), for O₃ it was 0.35 (95% CI: 0.11–0.58), and for ammonium (NH₄⁺) it was 0.25 (95% CI: 0.03–0.47), indicating synergistic risk. The most pronounced interactions were observed between NL and BC (HR= 1.85, 95% CI: 1.57–2.18) as well as NO₂ (HR = 1.63, 95% CI: 1.39–1.93). Concurrent exposure to high levels of NL and moderate levels of PM₂.₅ increased the risk by 61% (HR = 1.61, 95% CI: 1.29–1.99), while high levels of NL combined with black carbon resulted in an 85% increase in risk (HR = 1.85, 95% CI: 1.57–2.18).
conclusionsNL and air pollutants independently and synergistically elevate multimorbidity risk, with PM2.5 components (e.g., BC, NO3-) and O₃ exhibiting pronounced interactions. Policy interventions targeting light pollution reduction and air quality improvement are urgently needed to mitigate environmental health risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.